Opinion|Videos|November 16, 2026

Fixed-Duration Therapy and Frontline Pirtobrutinib in CLL

The panelists discussed how they individualize frontline treatment for chronic lymphocytic leukemia (CLL) now that fixed-duration and continuous regimens both hold strong guideline support.

The panelists discussed how they individualize frontline treatment for chronic lymphocytic leukemia (CLL) now that fixed-duration and continuous regimens both hold strong guideline support. They reviewed venetoclax-obinutuzumab, all-oral acalabrutinib plus venetoclax, the acalabrutinib triplet, and measurable residual disease-guided therapy alongside continuous Bruton tyrosine kinase (BTK) inhibitors. They noted that high-risk biology can favor continuous therapy, cardiac disease or anticoagulation can favor venetoclax, and renal impairment or tumor lysis risk can favor BTK inhibition, while ramp-up visits, infusions, travel distance, and patient preference also shape decisions. The panelists then discussed frontline pirtobrutinib, describing encouraging efficacy and tolerability but also weak comparators, short follow-up, and no head-to-head data against acalabrutinib or zanubrutinib. They identified older patients with atrial fibrillation, difficult-to-control hypertension, or other cardiac comorbidities who want continuous treatment as likely to benefit most, and they acknowledged that treatment after progression on frontline pirtobrutinib remains an open question.


Related to this article